Wedgewood Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

Wedgewood Investors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$322K	Hold	720	–	–	0.37%	70
2025 Q4	$326K	Buy	+720	New	+$310K	0.37%	64
2025 Q3	–	Sell	-720	Closed	-$321K	–	108
2025 Q2	$321K	Hold	720	–	–	0.37%	63
2025 Q1	$349K	Sell	720 -280	-28%	-$130K	0.41%	61
2024 Q4	$403K	Hold	1,000	–	–	0.47%	55
2024 Q3	$465K	Hold	1,000	–	–	0.51%	52
2024 Q2	$469K	Buy	+1,000	New	+$434K	0.56%	51
2023 Q4	$407K	Hold	1,000	–	–	0.51%	57
2023 Q3	$348K	Hold	1,000	–	–	0.47%	62
2023 Q2	$352K	Hold	1,000	–	–	0.45%	66
2023 Q1	$315K	Hold	1,000	–	–	0.41%	67
2022 Q4	$289K	Hold	1,000	–	–	0.38%	70
2022 Q3	$290K	Hold	1,000	–	–	0.45%	62
2022 Q2	$282K	Hold	1,000	–	–	0.4%	68
2022 Q1	$261K	Hold	1,000	–	–	0.32%	83
2021 Q4	$220K	Buy	+1,000	New	+$194K	0.26%	88
2021 Q3	–	Sell	-1,000	Closed	-$202K	–	95
2021 Q2	$202K	Hold	1,000	–	–	0.25%	93
2021 Q1	$215K	Hold	1,000	–	–	0.27%	93
2020 Q4	$236K	Hold	1,000	–	–	0.31%	81
2020 Q3	$272K	Hold	1,000	–	–	0.41%	66
2020 Q2	$290K	Hold	1,000	–	–	0.47%	62
2020 Q1	$238K	Hold	1,000	–	–	0.46%	63
2019 Q4	$219K	Buy	+1,000	New	+$202K	0.31%	83

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wedgewood Investors's VRTX Position: Q1 2026 in Review

Wedgewood Investors held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 720 shares worth $322K. The position accounts for 0.37% of the portfolio, ranked #70.

Wedgewood Investors first reported a position in VRTX in Q4 2019 and has held it in 23 quarters since. The position peaked at $469K in Q2 2024. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Wedgewood Investors held 720 shares of Vertex Pharmaceuticals worth $322K as of Q1 2026.
Wedgewood Investors left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.37% of Wedgewood Investors's portfolio in Q1 2026, its #70 holding.
Wedgewood Investors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
Wedgewood Investors's Vertex Pharmaceuticals position peaked at $469K in Q2 2024.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Wedgewood Investors's 13F filing for Q1 2026, filed 5 May 2026.